Denmark Outlines Vision For Decentralized Trials Beyond COVID-19
The Danish medicines regulator has set out its expectations on key elements of decentralized clinical trials as part of Denmark’s ongoing effort to develop a robust regulatory framework in this area.
You may also be interested in...
The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials.
A senior official from the European Medicines Agency says the COVID-19 pandemic has changed the future clinical trials landscape for good.
COVID-19 is driving changes to how clinical trials are being conducted in the US, with 44% of respondents who participated in a recent survey saying they have adapted or plan to become decentralized in coming months.